Cox Proportional Hazards Analysis for All Patients (n = 56) (A) and Patients Transplanted in CR2 (n = 31) (B) but Excluding Patients Relapsing Before BMT in an Isolated Extramedullary Site
| . | Hazard Rate Ratio . | [95% CI] . | Significance* . |
|---|---|---|---|
| A. (1) Univariate analysis | |||
| MRD | |||
| Negative | 1 | ||
| + | 3.14 | [0.99-9.96] | |
| ++ | 15.28 | [5.52-42.32] | P < .001 |
| Sex | |||
| M | 1 | ||
| F | 0.75 | [0.31-1.80] | NS (P = .509) |
| ALL subtype | |||
| B-lineage | 1 | ||
| T-lineage | 0.65 | [0.22-1.90] | NS (P = .410) |
| Ph′ | |||
| No | 1 | ||
| Yes | 1.35 | [0.50-3.62] | NS (P = .561) |
| Donor | |||
| Non-UD | 1 | ||
| UD | 1.20 | [0.45-3.22] | NS (P = .708) |
| aGVHD | |||
| 0 | 1 | ||
| 1 | 0.77 | [0.35-1.72] | NS (P = .523) |
| CR status | |||
| CR1 | 1 | ||
| CR2/3/4 | 1.48 | [0.61-3.56] | NS (P = .375) |
| Age (yr) at diagnosis | †0.0117 (SE 0.0454) | NS (P = .798) | |
| Age (yr) at BMT | †−0.0336 (SE 0.0490) | NS (P = .486) | |
| WCC (×109/L) at diagnosis | †−0.0007 (SE 0.0018) | NS (P = .669) | |
| (2) Multivariate analysis | |||
| MRD—adjusting for CR status, Ph′ and donor | |||
| Negative | 1 | ||
| + | 4.21 | [1.24-14.30] | |
| ++ | 23.65 | [7.05-79.33] | P < .001 |
| B. (1) Univariate analysis | |||
| MRD | |||
| Negative | 1 | ||
| + | 3.79 | [0.71-20.25] | |
| ++ | 13.91 | [3.21-60.30] | P < .001 |
| Ph′ | |||
| No | 1 | ||
| Yes | 3.99 | [0.49-32.47] | P = .275 |
| Donor | |||
| Non-UD | 1 | ||
| UD | 0.66 | [0.23-1.93] | P = .464 |
| Pre-BMT relapse during treatment | |||
| No | 1 | ||
| Yes | 8.38 | [2.83-24.83] | P < .001 |
| (2) Multivariate analysis | |||
| MRD—adjusted for on-treatment pre-BMT relapse and for Ph′ | |||
| Negative | 1 | ||
| + | 3.41 | [0.60-19.52] | |
| ++ | 6.50 | [1.22-34.68] | P = .058 |
| . | Hazard Rate Ratio . | [95% CI] . | Significance* . |
|---|---|---|---|
| A. (1) Univariate analysis | |||
| MRD | |||
| Negative | 1 | ||
| + | 3.14 | [0.99-9.96] | |
| ++ | 15.28 | [5.52-42.32] | P < .001 |
| Sex | |||
| M | 1 | ||
| F | 0.75 | [0.31-1.80] | NS (P = .509) |
| ALL subtype | |||
| B-lineage | 1 | ||
| T-lineage | 0.65 | [0.22-1.90] | NS (P = .410) |
| Ph′ | |||
| No | 1 | ||
| Yes | 1.35 | [0.50-3.62] | NS (P = .561) |
| Donor | |||
| Non-UD | 1 | ||
| UD | 1.20 | [0.45-3.22] | NS (P = .708) |
| aGVHD | |||
| 0 | 1 | ||
| 1 | 0.77 | [0.35-1.72] | NS (P = .523) |
| CR status | |||
| CR1 | 1 | ||
| CR2/3/4 | 1.48 | [0.61-3.56] | NS (P = .375) |
| Age (yr) at diagnosis | †0.0117 (SE 0.0454) | NS (P = .798) | |
| Age (yr) at BMT | †−0.0336 (SE 0.0490) | NS (P = .486) | |
| WCC (×109/L) at diagnosis | †−0.0007 (SE 0.0018) | NS (P = .669) | |
| (2) Multivariate analysis | |||
| MRD—adjusting for CR status, Ph′ and donor | |||
| Negative | 1 | ||
| + | 4.21 | [1.24-14.30] | |
| ++ | 23.65 | [7.05-79.33] | P < .001 |
| B. (1) Univariate analysis | |||
| MRD | |||
| Negative | 1 | ||
| + | 3.79 | [0.71-20.25] | |
| ++ | 13.91 | [3.21-60.30] | P < .001 |
| Ph′ | |||
| No | 1 | ||
| Yes | 3.99 | [0.49-32.47] | P = .275 |
| Donor | |||
| Non-UD | 1 | ||
| UD | 0.66 | [0.23-1.93] | P = .464 |
| Pre-BMT relapse during treatment | |||
| No | 1 | ||
| Yes | 8.38 | [2.83-24.83] | P < .001 |
| (2) Multivariate analysis | |||
| MRD—adjusted for on-treatment pre-BMT relapse and for Ph′ | |||
| Negative | 1 | ||
| + | 3.41 | [0.60-19.52] | |
| ++ | 6.50 | [1.22-34.68] | P = .058 |